Targeting autophagy in cancer: recent advances and future directions
RK Amaravadi, AC Kimmelman, J Debnath - Cancer discovery, 2019 - AACR
Autophagy, a multistep lysosomal degradation pathway that supports nutrient recycling and
metabolic adaptation, has been implicated as a process that regulates cancer. Although …
metabolic adaptation, has been implicated as a process that regulates cancer. Although …
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …
[HTML][HTML] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Abstract Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Background Sotorasib showed anticancer activity in patients with KRAS p. G12C–mutated
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was …
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …
Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors
Q Lei, D Wang, K Sun, L Wang… - Frontiers in cell and …, 2020 - frontiersin.org
In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …